Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the third quarter of 2025 compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved a revenue of 89.65 million yuan, a year-on-year decrease of 16.21% [1] - The net loss attributable to shareholders was 11.88 million yuan, with a year-on-year increase in loss of 1258.62% [1] - Basic earnings per share showed a loss of 0.09 yuan [1] Year-to-Date Performance - For the first three quarters of 2025, the company reported a total revenue of 272 million yuan, reflecting a year-on-year decline of 16.64% [1] - The net loss attributable to shareholders for the same period was 30.16 million yuan, compared to a net loss of 2.65 million yuan in the previous year [1] - Basic earnings per share for the first three quarters indicated a loss of 0.24 yuan [1]
拓新药业：第三季度归母净亏损1188.05万元